Individual Study / VALIANT

Valsartan in Acute Myocardial Infarction

Valsartan in Acute Myocardial Infarction

Initiatives -
In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients. *Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*

Members

Download
Investigators Contacts
  • Dr. Prof. Marc A. Pfeffer
    Harvard Medical School

Design

Study design
Clinical trial cohort
Follow Up
A median follow-up of 24.7 months,

Marker Paper

Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13;349(20):1893-906. doi: 10.1056/NEJMoa032292. Epub 2003 Nov 10. Erratum in: N Engl J Med. 2004 Jan 8;350(2):203.

PUBMED 14610160

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
14,703
Number of participants with biosamples
Supplementary Information
Patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both.

Access

Availability of data and biosamples

Data
Biosamples
Other